flurpiridaz
Small moleculeapprovedImaging agent
Approved
Sep 27, 2024
Clinical trial activity
4 trials · 2 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01347710)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
2020s
- Jan 1, 2020
General Electric — Earliest Phase 2 Sponsor(trial)
- Sep 27, 2024
Danaher — Earliest FDA Approval
- Sep 27, 2024
General Electric — Marketing Organization
- Sep 27, 2024
Danaher — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Approval history
- approvedSep 27, 2024
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)n1ncc(OCc2ccc(COCCF)cc2)c(Cl)c1=O- Mol. weight
- 368.84 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL494622 ↗
Also known as
- flurpiridaz
- flurpiridaz
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04594941 | Phase 2 | Oct 15, 2020 | General Electric |
| NCT03354273 | Phase 3 | Jun 8, 2018 | General Electric |
| NCT01681524 | Phase 3 | Nov 1, 2012 | Lantheus Medical Imaging |
| NCT01347710 | Phase 3 | Jun 1, 2011 | Lantheus Medical Imaging |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| General Electric | For profit | 2 | 2 | 2 | 2018 |
| Lantheus Medical Imaging | For profit | 2 | 2 | 1 | 2011 |
2 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Danaher | For profit | NDA | Sep 27, 2024 |
| General Electric | For profit | MKTG | Sep 27, 2024 |